Bayesian Capital Management’s Edwards Lifesciences EW Stock Holding History

Bayesian Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,077	Closed	-$567K	–	254
2026 Q1	$567K	Buy	+7,077	New	+$583K	0.69%	46
2025 Q4	–	Sell	-42,100	Closed	-$3.27M	–	263
2025 Q3	$3.27M	Buy	+42,100	New	+$3.29M	0.67%	23
2022 Q2	–	Sell	-5,399	Closed	-$636K	–	870
2022 Q1	$636K	Buy	+5,399	New	+$606K	0.09%	313
2021 Q1	–	Sell	-20,600	Closed	-$1.88M	–	581
2020 Q4	$1.88M	Sell	20,600 -8,600	-29%	-$713K	0.49%	47
2020 Q3	$2.33M	Buy	29,200 +9,500	+48%	+$741K	0.57%	34
2020 Q2	$1.36M	Buy	19,700 +10,400	+112%	+$739K	0.3%	87
2020 Q1	$585K	Sell	9,300 -56,700	-86%	-$4.09M	0.13%	247
2019 Q4	$5.13M	Buy	66,000 +57,300	+659%	+$4.47M	0.88%	12
2019 Q3	$638K	Buy	+8,700	New	+$611K	0.12%	229
2018 Q2	–	Sell	-36,687	Closed	-$1.71M	–	639
2018 Q1	$1.71M	Buy	+36,687	New	+$1.59M	0.43%	37
2017 Q4	–	Sell	-57,627	Closed	-$2.1M	–	594
2017 Q3	$2.1M	Buy	57,627 +33,900	+143%	+$1.29M	0.5%	42
2017 Q2	$935K	Buy	+23,727	New	+$866K	0.34%	86
2016 Q4	–	Sell	-23,436	Closed	-$942K	–	624
2016 Q3	$942K	Buy	23,436 +13,536	+137%	+$510K	0.62%	26
2016 Q2	$329K	Sell	9,900 -9,270	-48%	-$317K	0.2%	211
2016 Q1	$564K	Buy	19,170 +816	+4%	+$22.5K	0.53%	26
2015 Q4	$483K	Buy	+18,354	New	+$477K	0.69%	28

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Bayesian Capital Management's EW Position: Q2 2026 in Review

Bayesian Capital Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 7,077 shares — an estimated $567K sold.

Bayesian Capital Management first reported a position in EW in Q4 2015 and held it in 16 quarters. The position peaked at $5.13M in Q4 2019. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Bayesian Capital Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 7,077 Edwards Lifesciences shares in Q2 2026, an estimated $567K.
Bayesian Capital Management first reported a position in Edwards Lifesciences in Q4 2015 and held it in 16 quarters.
Bayesian Capital Management's Edwards Lifesciences position peaked at $5.13M in Q4 2019.
1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.